clinical trial · NCT04639180
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Jiangsu HengRui Medicine Co., Ltd.·phase3·active not recruiting·n = 687
Hepatocellular Carcinoma (HCC)CamrelizumabRivoceranib (Apatinib)
brief summary
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.
started
Apr 1, 2021
primary completion
Jul 31, 2026
completion
Jul 31, 2026
last updated
Dec 30, 2025
official title
A Randomized, Open-Label, Multi-Center, Phase Ⅲ Clinical Study of Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol